Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

NCT07518602 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)

Interventions

DRUG: Chidamide
DRUG: Sintilimab
DRUG: Bevacizumab

Sponsor

Sun Yat-sen University